Banma Intelligence Unveils AutoOmni 2.0, 23B On-Device Omni-Model
The MoE Model Matches Cloud Models 10x Its Size in Everyday Cockpit Tasks HANGZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Banma Intelligence Group introduced AutoOmni 2.0-23B-A3B, an omni-modal on-device LLM, at the Apsara Conference. Built on a...
Carbon Trade eXchange Launches CTX Corporate One for Institutional-Scale, High-Quality Carbon Credits
Free to open for the first time in 18 years, with a flat 10-cent fee per credit GOLD COAST, Australia and LONDON, Sept. 23, 2026 /PRNewswire/ -- Corporate One is built for large international project developers and corporate offtake brokers on the...
School Holiday, Grown-Up Edition: Agoda Spotlights Malaysian Escapes for Adults Who Need a Break Too
SINGAPORE, Sept. 23, 2026 /PRNewswire/ -- School holidays often come with family itineraries, early starts and plans built around the children. But adults need a break too. For some, that means a weekend away as a couple without the usual routine....
Rianlon takes its global ambitions to Malaysia
JOHOR BAHRU, Malaysia, SHANGHAI and HANGZHOU, China, Sept. 23, 2026 /PRNewswire/ -- This is a report from China Daily: For Li Haiping, chairman and CEO of Rianlon Corp, selling to the world is not enough to make a company truly global. "If research,...
Reap and Visa Collaborate to Launch Stablecoin Card Programs Across 100+ Markets
This collaboration expands Reap's Visa stablecoin-linked card programs globally. SINGAPORE, Sept. 23, 2026 /PRNewswire/ -- Reap, a global financial technology company building stablecoin-enabled infrastructure, and Visa, a global leader in digital...
ATTACK SHARK Redefines Esports Response with MEGA B2, Combining TMR Technology and Rapid Trigger
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- High-performance gaming peripheral brand ATTACK SHARK today launched the MEGA B2, a flagship gaming mouse featuring TMR-based Magnetic Micro-Switch with Rapid Trigger, customizable haptic feedback, dual 8K...
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the...
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. Singapore's Health Sciences Authority (HSA) has approved...